Hemophilia A Treatment Market [By Standard of Diagnosis (Mild Moderate & Severe), By Approved Drugs (Afstyla, Eloctate, Hemlibra, Kogenate FS, Kovaltry, Nuwiq & Obizur), By Care Delivery Model (Prophylaxis, On-demand therapy & Inhibitor therapy) and By Regions]: Market Estimate & Forecast, 2016 - 2022
Hemophilia A Treatment Market [By Standard of Diagnosis (Mild Moderate & Severe), By Approved Drugs (Afstyla, Eloctate, Hemlibra, Kogenate FS, Kovaltry, Nuwiq & Obizur), By Care Delivery Model (Prophylaxis, On-demand therapy & Inhibitor therapy) and By Regions]: Market Estimate & Forecast, 2016 - 2022
Hemophilia A patients have begun to shift from short acting to EHL factors and from on demand therapies to prophylactics. The increasing prevalent population of Hemophilia A and the rise in demand of the prophylactics treatments in developed markets will have a great impact on this market.